ABSTRACT Inherited factor VII (FVII) deficiency is
ity. Concerning the clinical phenotype, a correlation seems to exist between specific mutations and clinical symptoms.
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Coagulation factor VII is a vitamin K-dependent multidomain enzyme. This glycoprotein is synthesized with a 38-amino-acid pre-pro leader sequence containing a hydrophobic region targeting the protein for secretion (residues -36 to -24), and a pro sequence (residues -17 to -1) important for gamma-carboxylation. The mature protein is generated by cleavage of the Arg-Ala bond. The single-chain, 406-amino-acids protein has a molecular weight of 50,000. The multidomain enzyme is characterized by an amino-terminal gamma-carboxyglutamic acid-rich domain (Gla domain), two epidermal growth factor (EGF)-like domains, a connecting peptide, and a trypsin-like serine protease domain. In the connecting peptide, the cleavage site for factor Xa is an Arg152-Ile153 bond. The catalytic domain contains the catalytic triad His193, Asp242, and Ser344. FVIIa binds to its cellular receptor and catalytic cofactor, the transmembrane glycoprotein tissue factor (TF). Interaction of FVIIa with TF markedly enhances the catalytic activity of the serine protease. The FVIIa-TF complex initiates blood coagulation by virtue of its ability to activate factor X as well as factor IX. 1, 2 Inherited FVII deficiency is a rare autosomal recessive disorder. The human factor VII gene comprises nine exons spanning 12 kb 3 and is located at chromosome 13q34. Since the isolation and characterization of the human factor VII gene, the molecular basis of FVII deficiency was analyzed and more than 30 different single-base-pair substitutions and 4 short deletions were detected. 2, 4, 5 FVII activity is influenced not only by mutations of the factor VII gene but also by allelic polymorphic variations of the gene. Eight polymorphisms within FVII gene are known, 6,7 three of which influence the level of FVII activities: an insertion polymorphism of the promotor, 8 a repeat polymorphism within intron 7, 9-12 and the Arg353 Gln polymorphism of exon 8. 13 The hemorrhagic diathesis in patients with FVII deficiency can be highly variable and does not necessarily correlate with the level of FVII activities. The relationships between genotypes of mutations and polymorphisms of the FVII gene, FVII deficiency, and clinical phenotype were discussed for more than 40 patients with inherited FVII deficiency. Haplotypes for mutant alleles were determined in order to elucidate the origin of mutant alleles.
PATIENTS AND METHODS
Forty unrelated subjects with decreased or subnormal factor VII activities were studied. In addition, members of 19 families of patients with FVII deficiency were investigated. Identification of patients with FVII deficiency, clinical evaluation, and the analysis of the hemostaseological parameters were carried out in the home hospital.
DNA was extracted from white blood cells by the NaCl extraction method. 14 Mutations were detected by sequencing of the coding regions and exon-intron boundaries of the patient's DNA. The sequence reaction was performed as a cycle sequencing procedure using a Taq Dye Deoxy-Terminator Cycle sequencing kit (Perkin Elmer/Applied Biosystems, Warrington, England). All sequences were determined at least twice.
Eight polymorphisms in the FVII gene were identified by the following methods: The insertion polymorphism at nt-323 8 by polymerase chain reaction (PCR) or Eco-RI digestion of the PCR products, the His115 polymorphic site 15 by sequencing or Nla-III digestion of the PCR products, the variable repeats in intron 7 by PCR, 16 the dimorphisms Ala330 and Ser333 of exon 8 15, 17, 19 by sequencing, and the Arg353 Gln variation 13 by sequencing or Msp-I digestion of the PCR products. The found new DNA polymorphisms in the promoter region (Ϫ122T>C) and in intron 1a (73G>A) were detected by sequencing or restriction analysis by BmyI and MspI, respectively. 6, 7 
MUTATION SPECTRUM OF FACTOR VII DEFICIENCY
We have analysed the molecular defects of the factor VII gene in unrelated individuals with FVII deficiency by sequencing the coding region and the exonintron boundaries of the FVII gene. We have characterized 25 different mutations. 6 Six additional mutations were analyzed in this study. A transition 10656 C>T caused an Arg>Cys substitution in codon 247 of the catalytic region and the splice site mutation IVS2+1G>C. These mutations occurred in two related patients with strongly reduced FVII activity (FVII:C < 10%). Four other mutations were identified in homozygous or heterozygous patients with FVII activities ranging from 7 to 44 %. The splice site mutation IVS4+1G>A was analyzed in a homozygous patient with FVII activity of 7%. A 10710G>A transition caused a Glu265 Lys substitution in the catalytic domain. A transversion 10994G>C caused the Asp343 His substitution. A total of 29 different mutations were characterized (Table 1) , 20 of which are novel, not reported in the FVII mutation database of 1998. 5 All characterized lesions of the factor VII gene were single base substitutions, 22 (75.8%) were missense, two (6.9%) were nonsense, and five (17.2%) were splice site mutations. Nine (31%) of the mutations were transitions in CpG dinucleotides, which are known as mutation hot spots.
The mutations were localized in different parts of the FVII gene (Fig. 1) . About two thirds of the mutations affected the protease domain of FVII, indicating that loss of protease function is the most common cause of the clinical phenotype.
Most mutations were determined only once as private mutations of the affected patient or family. However, some mutations were found repeatedly in unrelated patients and families. The most frequent lesions are Ala294Val and Ala294Val;404delC. This mutation was first described by Arbini et al 20 in Polish patients and by Bernardi et al 21 in patients from Italy. According to our results, this mutation seems to be the most frequent one in Europe.
The donor splice mutation in intron 7 (IVS7+7) was identified in seven unrelated patients. This mutation was first described in Italy. 17 The frequencies of the other mutant alleles are shown in Table 1 .
GENOTYPE OF FVII MUTATIONS AND FVII DEFICIENCY
The influence of the genotype of the different mutations on FVII activity is shown in Tables 2 and 3 . In the homozygous condition the following mutations were detected in FVII deficiency (Table 2) : Val(-17) Ile, Phe4 Leu, Cys135Arg,Ala244Val, Ala294Val;404delC, and IVS4+1G>A. The factor VII activities were 8, <1, 1-4, 3, <1, and 7%, respectively. In 18 patients two different mutations were identified (double heterozygosity, Table  3 ). The FVII activities of 15 patients were in the range from 1 to 15%. The double heterozygous patients with IVS7+7 / Met298 Ile , IVS7+7 / Ala294 Val, and IVS7+7 / Ala206 Thr had FVII activities of 41, 23, and 30%, respectively.
In 14 patients only one FVII gene mutation was determined (heterozygosity). In 12 individuals the FVII activities ranged from 22 to 50%. Subnormal FVII activities (75 and 80%) were determined in two heterozygous persons for the donor splice mutation IVS7+7. Apparently, this lesion is a mild mutation. 17, 18 Two probands 8366, 8350 (see Table 3 ) showed FVII activities of <1 and 12%. The activity of these patients is in the range of homozygous and double heterozygous patients. Therefore we expect a second FVII mutation, but up to now we have not found a further mutation by sequencing. The strongly reduced FVII activities in patients 8366 (<1%) and 8350 (12%) are not explained by the heterozygosity of the repeat polymorphism in intron 7 (a/b) and the Arg353 Gln polymorphisms (M1/M2) alone (see the following).
FAMILY STUDIES AND HAPLOTYPE ANALYSIS
The factor VII activity is not only dependent on the homozygosity/double heterozygosity or heterozygosity of the mutations of the factor VII genes. The factor VII activity is also influenced by allelic polymorphic variations of the gene. As shown in Table 4 , eight polymorphisms within FVII gene are known, three of which influence the level of FVII activities.
Against this background we have determined the genotype of the following six different polymorphisms: the insertion (-323) and the (-122)C>T polymorphism of the promoter, the (73)G>A polymorphism of intron 1a, the His115 dimorphism of intron 5, the repeat polymorphism in intron 7, and the Arg353 Gln polymorphism of exon 8. The two codon dimorphisms Ala330 and Ser333 of exon 8, 15, 19 based on silent mutations, were never found in the patients we studied. In the Italian population the rare alleles were determined with frequencies of <1 and 1%. 15, 19 395 HEREDITARY FACTOR VII DEFICIENCY-HERRMANN ET AL.
FIG. 1.
The factor VII gene with mutations analyzed in patients with factor VII deficiency. * FVII mutations analyzed in this study, + FVII mutations published previously. 5 The influence of mutations and polymorphisms of FVII activity is more clearly demonstrated in family studies. In pedigree Bau FVII 1/96 ( Fig. 2A, page 398 ) the father (I,1) has a reduced FVII activity (75%) that is caused by heterozygosity of the insertion polymorphism (A1/A2), the repeat polymorphism of intron 7 (a/b), and the Arg353 Gln polymorphism (M1/M2). No FVII gene mutation was found by sequencing. The more reduced 
FVII activity of the mother (I,2, FVII:C 56%) is caused by heterozygosity of the missense mutation in codon 294 (Ala294 Val) combined with heterozygosity of the intron 7 repeat polymorphism (a/b) and of the Arg353 Gln polymorphism (M1/M2). Both children have inherited this mutation from the mother and their genotype concerning the polymorphisms is homozygous for the rare alleles of the repeat polymorphism in intron 7 (a/a) and of the Arg353 Gln polymorphism (M2/M2) as well as heterozygous for the insertion polymorphism (A1/A2). The FVII activity in daughter (II,2) was much more decreased (about 30%) than in her mother. The reason for the decreased FVII level seems to be the combination of homozygosity and heterozygosity for the rare alleles of the polymorphisms (A1/A2,a/a,M2/M2) with the missense mutation Ala294 Val in the FVII gene.
The different levels of FVII activity and FVII antigen in the family members of pedigree Hi-FVII 3/96 (Fig. 2B) are explained in the same way. Finally, the double heterozygosity for two different mutations and the heterozygosity of the rare polymorphic alleles (a, M2) caused the extremely reduced FVII activity (FVII:C 1,3%) and FVII antigen (FVII:Ag 0,9%) in patient 3698 (II,2).
On the basis of molecular genetic studies of families with FVII deficiency, we are able to determine the haplotype of polymorphisms that are linked to specific mutations. As shown in family Hi-FVII 3/96 (Fig. 2B) , the FVII mutation Arg152 stop is linked to haplotype A1, P1,G1,H1,b,M1 and the Ala294 Val;404delC mutation to haplotype A1,P1,G1,H2,a,M2. The last haplotype was analyzed in all mutant alleles with the Ala294 Val 397 HEREDITARY FACTOR VII DEFICIENCY-HERRMANN ET AL. substitution. Identical haplotypes based on the six intragenic FVII polymorphisms were also determined for other amino acid substitutions that we found repeatedly in our population: Val281 Phe (A1,P1,G1,H1,b,M1), Val252 Met (A2,P2,G2,H2,a,M2), and Cys135Arg (M, P1, G1, H1, b,M1). For the frequent variation in the donor splice site of intron 7 (IVS7+7, 9733A>G) the haplotype A2,P2,G2,H2,b,M2 was determined in all mutant alleles. These results suggest the probably common origin of the mutations in the population studied.
Haplotype analysis of a patient from Lebanon (patient 3719) and her family shows that the FVII genes bearing the Ala244 Val mutation have the same haplotype as that of Jewish patients from Morocco, Iran, Iraq, and Bukhara. 22 Tamary et al 22 discussed a founder effect for the mutation in Moroccan and Iranian Jews. The 9717G>A mutation codon 206, which caused the Ala>Thr substitution, was detected twice, but each allele was linked to a different haplotype (A1,P1,G1, H1,b,M1 and A2,P2,G2, H2,a,M2). This mutation probably has different origins in the families studied.
GENOTYPE AND CLINICAL PHENOTYPE
Variations of the clinical symptoms were remarkable in patients with very low levels of FVII activity caused by homozygosity for different mutations ( Table  2) . Extremely severe clinical symptoms were found in a homozygous patient with a Cys135 Arg substitution (FVII:C 1-4%, Table 2 ). The severe bleeding tendency required prophylactic FVII substitution. 23 Epistaxis, hypermenorrhagia, joint bleeding after trauma, and bloody stools are the symptoms in homozygotes for Phe4 Leu (FVII:C < 1%), Ala244 Val (FVII:C 3, 4%) and Ala294 Val;404delC (FVII < 1%), and IVS4+1 (FVII:C 7%). On the other hand, homozygosity for Val (-17) Ile with FVII activity of 8% is characterized by postpartum brain hematomas but no other bleeding episodes.
Double heterozygosity of the following mutations causes severe clinical features (Table 3) In double heterozygous patients with less reduced FVII activities (FVII:C between 9 and 15% ) the clinical phenotype is very variable. Some double heterozygous cases have clinical symptoms; others are asymptomatic. The double heterozygous patient 3677 (Gly156 Asp / Ala294 Val;404delC) with FVII activity of 15% had frequent epistaxis and gingival bleeding, which required transfusion. On the other hand, double heterozygous patients for Ala206 Thr / Pro303 Arg and Leu(-20) Pro / Val252 Met showing FVII activities in the same range (15 and 11%) were asymptomatic.
In this context the clinical symptoms of double heterozygosity for the donor splice mutations IVS7+7 with other mutations are interesting. Only double heterozygosity for the Ser60 Pro substitution decreased the FVII activity below 9% and was associated with clinical symptoms (menorrhagia). The three other double heterozygotes (IVS7+7 / Ala294 Val, IVS7+7 / Met298 Ile, IVS7+7 / Ala206 Thr) had FVII activities of 23, 41, and 30% respectively, and these patients were asymptomatic. IVS7+7 is apparently a mild mutation. 17, 18 It is known that the clinical features of inherited FVII deficiency are quite variable. The correlation between reported coagulation activity and clinical bleeding tendency is rather poor. 2, 4 The individuals who are homozygous or double heterozygous for FVII gene mutations seem to be more severely affected and heterozygotes are mostly asymptomatic. Specific mutations seem to cause extremely severe clinical symptoms as shown for homozygosity of the Cys135 Arg substitution 23 , Ala294Val; 404delC as well as for homozygosity of the IVS4+1G>A mutation. 24, 25 26 This was the second case of inhibitor formation after treatment with rFVIIa among 13 FVII-deficient patients. Therefore, the authors recommended testing frequently for inhibitor development if the drug is used as first-line treatment for FVII-deficient patients, especially children.
There is a rather poor correlation between the clinical symptoms and the FVII activity. The double heterozygous patient with Gly156 Asp / Ala294 Val;404delC had clinical symptoms that required transfusion, whereas patients with double heterozygosity for Ala206 Thr / Pro303 Arg and Leu(-20) Pro / Val252 Met were asymptomatic. All these patients have nearly the same FVII activity, ranging between 11and 15%.
Usually, heterozygotes are mostly asymptomatic, but some heterozygotes for specific mutations have mild symptoms (4 of 14 heterozygotes). Three of nine heterozygotes for Ala294 Val;404delC showed rare epistaxis, gingival bleeding, and a mild bleeding tendency, respectively. One heterozygote for the Glu265 Lys substitution (FVII:C 44%) had frequent epistaxis in childhood.
Concerning the clinical phenotype, a correlation seems to exist with specific mutations. Further studies of the molecular genetics of FVII deficiency are necessary in order to understand the correlation between specific mutations and clinical phenotypes. In severe cases of FVII deficiency, the molecular diagnosis for detection of the specific mutations and haplotype analysis of polymorphisms are necessary to provide genetic counseling for families at risk.
